Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer

Journal of Nuclear Medicine

Volumn 37, Issue 12, 1996, Pages 1962-1964

  Grünwald, Frank ^a   Menzel, Christian ^a   Fimmers, Rolf ^a   Zamora, Paul O ^a   Biersack, Hans J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

prognosis; radioiodine therapy; thyroglobulin; thyroid cancer

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER RECURRENCE; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RADIOIODINATION; RELIABILITY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 0030455959     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hotze AL, Bockisch A, Ruhlmann J, Grünwald F, Horst M, Biersack HJ. Serum thyroglobulin in nontoxic goiter. Eur J Nucl Med 1989;15:520.
2. Hotze AL, Bockisch A, Briele B, Horst M, Ruhlmann J. Biersack HJ. Therapy of nontoxic goiter with levothyroxine and a iodide-levothyroxine compound preparation. Nuc Compact 1989;20:166-170.
3. Van Herle AJ, Uller RP. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinoma. J Clin Invest 1975;56:272-277.
4. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurement and iodine-131 total-body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981;71:806-814.
5. 131I treatment on thyroglobulin measurement in the follow-up of patients with thyroid cancer. Thyroid 1994;4:239-242.
6. Blahd WH. Serum thyroglobulin in the management of thyroid cancer [Editorial]. J Nucl Med 1990;31:1771-1773.
7. Schlumberger M, Fragu P, Gardet P, Lumbroso J, Violot D, Parmentier C. A new immunoradiometric assay (IRMA) system for thyroglobulin measurement in the follow-up of thyroid cancer patients. Eur J Nucl Med 1991;18:153-157.
8. Hotze AL, Briele B, Grünwald F, et al. Determination of serum human thyroglobulin (hTg) with a new IRMA-system in patients with differentiated thyroid carcinoma. Radiology Diag 1991;32:383-386.
9. Roti E, Robuschi G, Emanuele R, et al. The value of serum thyroglobulin measurement as a marker of cancer in the follow-up of patients previously treated for differentiated thyroid tumor. J Endocrinol Invest 1982;5:43-46.
10. Girelli ME, Busnardo B, Amerio R, Casara D, Betterle C, Piccolo M. Clinical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total-body scan: results in 291 patients with thyroid cancer. Eur J Nucl Med 1986;11:333-335.
11. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, Degroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
12. Aiello DP, Manni A. Thyroglobulin measurement versus iodine-131 total-body scan for follow-up of well-differentiated thyroid cancer. Arch Intern Med 1990;150:437-439.
13. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the postsurgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990;31:1766-1771.
14. Lubin E, Mechlis-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994;35:257-262.
15. Charles MA, Dodson LE, Waldeck N, et al. Serum thyroglobulin levels predict total-body iodine scan findings in patients with treated well-differentiated thyroid carcinoma. Am J Med 1980;69:401-407.
16. McDougall R, Bayer MF. Follow-up of patients with differentiated cancer using serum thyroglobulin measured by immunoradiometric assay. Comparison with 1-131 total-body scan. J Nucl Med 1980;21:741-744.
17. Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L. Serum thyroglobulin concentrations and iodine-131 whole-body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol 1980;13:107-111.
18. Echenique RL, Kasi L, Haynie TP, Glenn HJ, Samaan NA, Hill CS. Clinical evaluation of serum thyroglobulin levels and iodine-131 scans in post-therapy patients with differentiated thyroid carcinoma: concise communication. J Nucl Med 1982;23:235-240.
19. Tourniaire J, Bernard MH, Ayzac L, Nicolas MH, Bornet H. Serum thyroglobulin assay after total unilateral thyroid lobectomy for differentiated thyroid carcinoma. Presse Med 1990;19:1309-1312.
20. Grünwald F, Schomburg A, Menzel C, et al. Blood count changes after radioiodine treatment in thyroid carcinoma. Med Klin 1994;89:522-528.
21. Biersack HJ, Hotze A. The clinician and the thyroid. Eur J Nucl Med 1991;18:761-778.
22. Grünwald F, Ullmann P, Fimmers R, Hotze A, Biersack HJ. Influence of TNM stage and other parameters on the prognosis of thyroid tumors. In: Reinwein D, Weinheimer B, eds. Schilddrüse 1993. Therapie der Hyperthyreose. Berlin-New York: Walter de Gruyter; 1994:533-535.
23. DeGroot LJ, Kaplan EL, McCormick, M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
24. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720.